Publicaciones en colaboración con investigadores/as de Hospital Vega Baja (6)

2023

  1. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

2022

  1. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  2. Role of vericiguat in the overall etiopathogenesis of heart failure with reduced ejection fraction. Current position

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 8-14

  3. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

  4. Therapeutic approach to patients with heart failure with reduced ejection fraction. The role of vericiguat

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 23-29

  5. Vericiguat in heart failure: from scientific evidence to clinical practice

    Revista Clinica Espanola